397 related articles for article (PubMed ID: 33736651)
1. Third-line therapy for chronic myeloid leukemia: current status and future directions.
Cortes J; Lang F
J Hematol Oncol; 2021 Mar; 14(1):44. PubMed ID: 33736651
[TBL] [Abstract][Full Text] [Related]
2. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Hochhaus A; Ernst T; Eigendorff E; La Rosée P
Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic approaches in chronic myeloid leukemia.
Özgür Yurttaş N; Eşkazan AE
Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Yilmaz M; Jabbour E
Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
[TBL] [Abstract][Full Text] [Related]
5. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
[TBL] [Abstract][Full Text] [Related]
6. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
7. The role of bosutinib in the treatment of chronic myeloid leukemia.
Gambacorti-Passerini C; le Coutre P; Piazza R
Future Oncol; 2020 Jan; 16(2):4395-4408. PubMed ID: 31833784
[TBL] [Abstract][Full Text] [Related]
8. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Hall KH; Brooks A; Waller EK
Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
[No Abstract] [Full Text] [Related]
9. Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Rusconi F; Piazza R; Vagge E; Gambacorti-Passerini C
Expert Opin Pharmacother; 2014 Apr; 15(5):701-10. PubMed ID: 24479382
[TBL] [Abstract][Full Text] [Related]
10. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
13. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Lee H; Basso IN; Kim DDH
Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
[TBL] [Abstract][Full Text] [Related]
14. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D; Hughes TP
Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
16. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
[TBL] [Abstract][Full Text] [Related]
17. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]